1227 related articles for article (PubMed ID: 31475572)
1. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
[TBL] [Abstract][Full Text] [Related]
2. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
[TBL] [Abstract][Full Text] [Related]
3. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
4. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
5. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
Szarek M; Steg PG; DiCenso D; Bhatt DL; Bittner VA; Budaj A; Diaz R; Goodman SG; Gotcheva N; Jukema JW; Pordy R; Roe MT; Sourdille T; White HD; Xavier D; Zeiher AM; Schwartz GG
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005858. PubMed ID: 31707826
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
11. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
[TBL] [Abstract][Full Text] [Related]
12. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
[TBL] [Abstract][Full Text] [Related]
14. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
[TBL] [Abstract][Full Text] [Related]
16. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Diaz R; Li QH; Bhatt DL; Bittner VA; Baccara-Dinet MT; Goodman SG; Jukema JW; Kimura T; Parkhomenko A; Pordy R; Reiner Ž; Roe MT; Szarek M; Tse HF; White HD; Zahger D; Zeiher AM; Schwartz GG; Steg PG;
Eur J Prev Cardiol; 2021 Mar; 28(1):33-43. PubMed ID: 33755145
[TBL] [Abstract][Full Text] [Related]
17. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
Board C; Kelly MS; Shapiro MD; Dixon DL
J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
[TBL] [Abstract][Full Text] [Related]
19. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Quintero K; Roe MT; Sasiela WJ; Tamby JF; Tricoci P; White HD; Zeiher AM;
N Engl J Med; 2018 Nov; 379(22):2097-2107. PubMed ID: 30403574
[TBL] [Abstract][Full Text] [Related]
20. Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Steg PG; Szarek M; Bhatt DL; Bittner VA; Brégeault MF; Dalby AJ; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Ostadal P; Parkhomenko A; Pordy R; Roe MT; Tricoci P; Vogel R; White HD; Zeiher AM; Schwartz GG
Circulation; 2019 Jul; 140(2):103-112. PubMed ID: 31117810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]